Dietary tocopherols inhibit cell proliferation, regulate expression of ERα, PPARγ, and Nrf2, and decrease serum inflammatory markers during the development of mammary hyperplasia

Molecular Carcinogenesis

Volumn 52, Issue 7, 2013, Pages 514-525

  Smolarek, Amanda K ^a   So, Jae Young ^a   Thomas, Paul E ^a   Lee, Hong Jin ^a,b   Paul, Shiby ^a   Dombrowski, Anne ^a   Wang, Chung Xiou ^a   Saw, Constance Lay Lay ^a   Khor, Tin Oo ^a   Kong, Ah Ng Tony ^a,c   Reuhl, Kenneth ^a   Lee, Mao Jung ^a   Yang, Chung S ^a,c   Suh, Nanjoo ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b Chung Ang University   (South Korea)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Breast cancer; Estrogen receptor; Peroxisome proliferator activated receptor ; Tocopherol; Vitamin E

Indexed keywords

8 ISOPROSTANE; CASPASE 3; CELL NUCLEUS ANTIGEN; CYCLOOXYGENASE 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GAMMA TOCOPHEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOGENESIS; BREAST HYPERPLASIA; CELL PROLIFERATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; ESTRADIOL BLOOD LEVEL; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION;

ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DIET; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; INFLAMMATION MEDIATORS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICROSOMES, LIVER; NF-E2-RELATED FACTOR 2; PPAR GAMMA; RATS; RATS, INBRED ACI; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOCOPHEROLS; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; RATTUS; RODENTIA;

EID: 84879460535     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21886     Document Type: Article

References (41)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212- 236.
2. Taylor PR, Qiao YL, Abnet CC, et al. Prospective study of serum vitamin E levels and esophageal and gastric cancers. J Natl Cancer Inst 2003; 95: 1414- 1416.
3. Constantinou C, Papas A, Constantinou AI. Vitamin E and cancer: An insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer 2008; 123: 739- 752.
4. Jiang Q, Christen S, Shigenaga MK, et al. gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr 2001; 74: 714- 722.
5. Brigelius-Flohe R, Kelly FJ, Salonen JT, et al. The European perspective on vitamin E: Current knowledge and future research. Am J Clin Nutr 2002; 76: 703- 716.
6. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: The Women's Health Study: A randomized controlled trial. JAMA 2005; 294: 56- 65.
7. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005; 97: 481- 488.
8. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39- 51.
9. Huang HY, Appel LJ. Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans. J Nutr 2003; 133: 3137- 3140.
10. Campbell SE, Stone WL, Whaley SG, et al. Gamma (gamma) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (gamma) expression in SW 480 human colon cancer cell lines. BMC Cancer 2003; 3: 25.
11. Jiang Q, Ames BN. Gamma-tocopherol, but not alpha-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J 2003; 17: 816- 822.
12. Jiang Q, Elson-Schwab I, Courtemanche C, et al. Gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci USA 2000; 97: 11494- 11499.
13. Christen S, Woodall AA, Shigenaga MK, et al. gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: Physiological implications. Proc Natl Acad Sci USA 1997; 94: 3217- 3222.
14. Lee HJ, Ju J, Paul S, et al. Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma. Clin Cancer Res 2009; 15: 4242- 4249.
15. Chan MM, Lu X, Merchant FM, et al. Gene expression profiling of NMU-induced rat mammary tumors: Cross species comparison with human breast cancer. Carcinogenesis 2005; 26: 1343- 1353.
16. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med 2010; 7: e1000279.
17. Harvell DM, Strecker TE, Tochacek M, et al. Rat strain-specific actions of 17beta-estradiol in the mammary gland: Correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci USA 2000; 97: 2779- 2784.
18. Shull JD, Spady TJ, Snyder MC, et al. Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma. Carcinogenesis 1997; 18: 1595- 1601.
19. Li SA, Weroha SJ, Tawfik O, et al. Prevention of solely estrogen-induced mammary tumors in female aci rats by tamoxifen: AT for estrogen receptor mediation. J Endocrinol 2002; 175: 297- 305.
20. Turan VK, Sanchez RI, Li JJ, et al. The effects of steroidal estrogens in ACI rat mammary carcinogenesis: 17beta-estradiol, 2-hydroxyestradiol, 4-hydroxyestradiol, 16alpha-hydroxyestradiol, and 4-hydroxyestrone. J Endocrinol 2004; 183: 91- 99.
21. Ju J, Hao X, Lee MJ, et al. A gamma-tocopherol-rich mixture of tocopherols inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sulfate sodium-treated mice. Cancer Prev Res (PhilaPa) 2009; 2: 143- 152.
22. Zhao Y, Lee MJ, Cheung C, et al. Analysis of multiple metabolites of tocopherols and tocotrienols in mice and humans. J Agric Food Chem 2010; 58: 4844- 4852.
23. Jan YH, Mishin V, Busch CM, et al. Generation of specific antibodies and their use to characterize sex differences in four rat P450 3A enzymes following vehicle and pregnenolone 16alpha-carbonitrile treatment. Arch Biochem Biophys 2006; 446: 101- 110.
24. Lee HJ, Liu H, Goodman C, et al. Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. Biochem Pharmacol 2006; 72: 332- 343.
25. Ravoori S, Vadhanam MV, Sahoo S, et al. Mammary tumor induction in ACI rats exposed to low levels of 17beta-estradiol. Int J Oncol 2007; 31: 113- 120.
26. Kurz SG, Hansen KK, McLaughlin MT, et al. Tissue-specific actions of the Ept1, Ept2, Ept6, and Ept9 genetic determinants of responsiveness to estrogens in the female rat. Endocrinology 2008; 149: 3850- 3859.
27. Li GX, Lee MJ, Liu AB, et al. delta-tocopherol is more active than alpha-or gamma-tocopherol in inhibiting lung tumorigenesis in vivo. Cancer Prev Res (Phila) 2011; 4: 404- 413.
28. Sontag TJ, Parker RS. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. J Biol Chem 2002; 277: 25290- 25296.
29. Mense SM, Remotti F, Bhan A, et al. Estrogen-induced breast cancer: Alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol Appl Pharmacol 2008; 232: 78- 85.
30. Chamras H, Barsky SH, Ardashian A, et al. Novel interactions of vitamin E and estrogen in breast cancer. Nutr Cancer 2005; 52: 43- 48.
31. Bonofiglio D, Gabriele S, Aquila S, et al. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clin Cancer Res 2005; 11: 6139- 6147.
32. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: Complex stories. Nat Rev Cancer 2004; 4: 61- 70.
33. Campbell SE, Musich PR, Whaley SG, et al. Gamma tocopherol upregulates the expression of 15-S-HETE and induces growth arrest through a PPAR gamma-dependent mechanism in PC-3 human prostate cancer cells. Nutr Cancer 2009; 61: 649- 662.
34. Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: A promising therapeutic target. Cancer Biol Ther 2009; 8: 6- 15.
35. Schulz TJ, Thierbach R, Voigt A, et al. Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem 2006; 281: 977- 981.
36. Jarrar MH, Baranova A. PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: The importance of interplay with TGFbeta signalling. J Cell Mol Med 2007; 11: 71- 87.
37. Frohlich DA, McCabe MT, Arnold RS, et al. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene 2008; 27: 4353- 4362.
38. Barve A, Khor TO, Nair S, et al. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int J Cancer 2009; 124: 1693- 1699.
39. Yu S, Khor TO, Cheung KL, et al. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS One 2010; 5: e8579.
40. Yao Y, Brodie AM, Davidson NE, et al. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Treat 2010; 124: 585- 591.
41. Lu G, Xiao H, Li GX, et al. A gamma-tocopherol-rich mixture of tocopherols inhibits chemically induced lung tumorigenesis in A/J mice and xenograft tumor growth. Carcinogenesis 2010; 31: 687- 694.